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As the prevalence of diabetes mellitus is substantially increasing worldwide, associated diseases such as renal failure, cardiovas-
cular diseases, fatty liver, and cancers have also increased. A number of cancers such as pancreatic, liver, breast, and female re-
productive cancers have shown an increased prevalence and a higher mortality rate in diabetic patients compared to healthy 
subjects. Thus, this suggests an association between diabetes, especially type 2 diabetes and cancer incidence and progression. 
Recent studies have suggested that hyperinsulinemia, chronic inflammation and hyperglycemia, all frequently seen in diabetics, 
may lead to increased tumor growth; the underlying molecular mechanisms of this association are not fully understood. In par-
ticular, chronic hyperglycemic episodes could serve as a direct or indirect mediator of the increase in tumor cell growth. Here, 
we will discuss our current understanding how hyperglycemia and cancer risk may be linked, and what the implications are for 
the treatment of diabetic cancer patients. 
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INTRODUCTION
Extensive epidemiological studies suggest that certain types of 
cancers show a higher prevalence rate and a higher risk of mor-
tality in a patient population suffering from diabetes mellitus 
(DM) [1]. Liver and pancreatic cancers show a strong relation-
ship with DM, and both of these organs play a central role in 
the pathophysiology of diabetes [1-3]. Other cancers, such as 
colorectal, breast, endometrial and renal, and renal cancer also 
show an association with DM, whereas prostate cancer appears 
to have a negative association with DM [4]. Thus, it is now evi-
dent that a higher cancer risk and mortality rate is observed in 
DM patients compared to euglycemic individuals. Further-
more, DM and cancer are frequently diagnosed in the same in-
dividuals [5], suggesting that those two diseases share the com-
mon risk factors and pathophysiological mechanisms. The un-
derlying mechanisms behind this association have not been 
fully elucidated; however, plausible connections consist of hy-
perinsulinemia, insulin resistance, chronic inflammation, oxi-
dative stress, and hyperglycemia; all of these factors potentially 
promote tumor progression in various ways [6-10]. The impact 
of insulin, insulin-like growth factor-1 (IGF-1) and chronic in-
flammation in cancer progression has been extensively studied, 
whereas effects of hyperglycemia on cancer have received less 
attention, although hyperglycemia is one of the most widely 
studied metabolic changes in DM. 
 Hyperglycemia is defined as a state of excess glucose con-
centration in circulation, a hallmark for both type 1 DM and 
type 2 DM. Due to insufficient insulin production in pancreatic 
β cells, hyperglycemia develops in type 1 DM. Additionally, the 
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increase of systemic insulin resistance in type 2 DM leads to 
hyperglycemia as well [1]. Hyperglycemia indirectly influences 
cancer cells through an increase in the levels of insulin/IGF-1 
and inflammatory cytokines in circulation. Beyond that, there 
are reasons to believe that hyperglycemia per se has a direct im-
pact on cancer cell proliferation, apoptosis and metastasis [1-3]. 
High glucose activates various signaling pathways that coop-
erate to control cancer cell behavior, such as proliferation, mi-
gration, invasion and recurrence [11]. Furthermore, epigene-
tic modulations of oncogenic pathways induced by high glu-
cose result in prolonged activation of cancer cell proliferation 
[12,13]. However, these direct effects of high glucose in cancer 
cell behavior are relatively unexplored, and more needs to be 
learned about which signaling pathways are involved and how 
they are controlled. Resolving these questions will shed light 
on the molecular links between DM and cancers. Below, we 
will discuss the potential mechanisms linking hyperglycemia 
to cancer progression, with a special focus on tumor cell pro-
liferation, apoptosis, invasion and the epigenetic variations in 
cancer cells upon hyperglycemic exposure. This will by neces-
sity also require a discussion of the efficacy of DM therapeu-
tics  for cancer growth.
 
IMPACT OF HYPERGLYCEMIA ON CANCER 
CELL BEHAVIOR
Cancer cell proliferation
Enhanced glucose uptake in cancer cells is a well-established 
hallmark of cancer cells [14]. The enhanced glucose metabo-
lism in cancer cells is referred to as the Warburg effect, which 
comprises the increase in aerobic glycolysis in cancer cells de-
fined by Warburg [15]. In this respect, hyperglycemia could 
provide a high glucose fuel source for cancer cells supporting 
rapid proliferation. Indeed, in vitro studies with cancer cell 
lines indicate that high concentrations of glucose levels regulate 
enhanced expression of genes associated with promoting can-
cer cell proliferation, invasion, and migration [16]. In vivo ani-
mal studies are plagued by technical limitations to evaluate the 
effects of hyperglycemia on cancer cells. This is due to the fact 
that in order to induce hyperglycemia in these rodent models, 
streptozotocin is used to destroy pancreatic β-cells. This leads 
to hyperglycemia, but obviously also prompts the loss of insu-
lin in circulation. Insulin is an intrinsic mitogen affecting tu-
mor growth. In humans, elevated glucose levels in circulation 
serve as an established predictor of poor survival in cancer pa-
tients [17-19]. In line with that, high sugar intake is associated 
with increased cancer cell proliferation [16].
 Multiple proteins have been implicated as mediators of hy-
perglycemia and cancer cell proliferation (Fig. 1). Recent in vitro 
studies suggest that the expression of glucose transporters, such 
as the GLUT1 and GLUT3 isoforms, is regulated under hyper-
glycemic conditions in JAR cells, a choriocarcinoma cell line 
[20]. Hyperglycemic conditions in vitro (such as 25 mM D-glu-
cose) trigger increased glucose uptake in JAR cells due to a tran-
scriptional increase and enhanced protein levels for GLUT1 and 
GLUT3 [20]. Growth factors, such as epidermal growth factor 
(EGF) levels are augmented by high glucose treatment in pan-
creatic cancer cell lines, such as BxPC-3 and Panc-1, and subse-
quently activate its receptor, the epidermal growth factor recep-
tor (EGFR), a well-known oncogenic pathway [21]. In addition, 
the levels of protein kinase C (PKC) and peroxisome prolifera-
tor-activated receptors (PPARs) are stimulated under hypergly-
cemic conditions in MCF-7 human breast cancer cells [22]. 
Overexpression of PKC-α in MCF-7 induces a more aggressive 
phenotype [23]. PPAR-α and PPAR-γ are influencing lipid met-
abolic pathways. High levels of PPAR-α and PPAR-γ can accel-
erate cell proliferation [24]. High glucose accelerates the cell cy-
cle through regulating the levels of key proteins, such as cyclin-
dependent kinase 2, E2F, cyclinA, and cyclinE, resulting in in-
creased proliferation [16]. Furthermore, hyperglycemic condi-
tions augment the levels of glial cell line derived neurotophic 
factor (GDNF) and its tyrosine kinase receptor gene, the rear-
ranged during transfection (RET) gene, in human pancreatic 
cancer cells, such as BxPC-3 and MIA PaCa-2 cells [25]. GDNF 
is a cytokine related to the transforming growth factor-β family, 
enhancing the survival and differentiation of midbrain dopa-
minergic neurons [26] as well as promoting pancreatic cancer 
cell proliferation and invasion mediated through a protein 
complex of RET/GDNF-family receptor α-1 (GFR α-1) [27]. 
Taken together, these data strongly implicate hyperglycemia as 
a contributing factor leading to enhanced cell proliferation. 
Cancer cell antiapoptosis
Apoptosis, the process of programmed cell death, is a geneti-
cally regulated process that is essential for multicellular organ-
isms. The dysregulation of apoptosis can result in uncontrolled 
cellular growth [28]. The connection between hyperglycemia 
and cancer cell apoptosis is unclear; however, there are several 
possible connections suggested (Fig. 1).
 Many tumors are exposed to hypoxia due to limited oxygen 
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supplies during rapid anabolic cell proliferation [29]. In re-
sponse to hypoxia, hypoxia inducible factor-1α (HIF1α), a key 
transcriptional regulator of the hypoxic response, is stabilized 
at the protein level and translocated into nucleus. This leads to 
the increased expression of genes associated with glucose me-
tabolism, angiogenesis and survival/antiapoptotic processes 
[30,31]. Under normoxic conditions, HIF1α is degraded by 
HIF prolyl hydroxylase (PHD) enzymes, and this process is oxy-
gen dependent [31]. Hyperglycemia regulates the stability and 
function of HIF1α through interfering with the degradation of 
HIF1α by PHD enzymes [32], which causes increased cancer cell 
survival and conveys antiapoptotic qualities upon the tumor.
 Recent studies also suggest that glucose metabolism in can-
cer cells protects cytochrome c-mediated apoptosis [33]. Gluta-
thione is one of the main antioxidant mediators of cells, which 
is reduced by nicotinamide adenine dinucleotide phosphate 
(NADPH) derived from enhanced glucose metabolism, such as 
the pentose phosphate pathway [34]. 
Cancer cell migration and invasiveness
Epidemiological data suggest that metastatic growth is the 
main cause of deaths in 90% patients carrying solid tumors 
[35]. Metastatic growth ensues when cancer cells become inva-
sive through an altered phenotype, penetrating into the circula-
tory system, and taking hold in a distant organ. Epithelial-mes-
enchymal transition (EMT), a multifaceted process critical for 
the acquisition of migration, invasiveness and pluripotent stem 
cell-like phenotype, plays a pivotal role in the metastatic pro-
cess [36]. Several studies suggest that high glucose induces can-
cer cell invasiveness and migration through stimulating EMT 
(Fig. 1). High glucose decreases E-cadherin levels, an epithelial 
cell marker, and increases the PKC-α pathway, leading to a 
more invasive phenotype [16]. Recently, Dong et al. [37] sug-
gested that hyperglycemia induces the EMT phenotype and the 
Hyperglycemia
Tumor progression
Hyperglycemic memory
Epigenetic regulation
NF-κB↑
Nrg1 ↑
Oncogenic pathways
Cancer cell migration
and invasiveness
SOD and uPA ↑
ZIP6 and ZIP10 ↑
Cancer cell antiapoptosis
HIF1α ↑
PHD enzyme  ↓
Cytochrome c mediated
apoptosis ↓
GULT1 and GULT3 ↑
EGF and EGFR ↑
PKC-α ↑
PPAR-α and PPAR-γ ↑
GDNF and RET receptor 
Cancer cell proliferation
Fig. 1. Impact of hyperglycemia on tumor progression. A hyperglycemic environment contributes to tumor progression through 
multiple pathways. Cancer cell proliferation is promoted by the up-regulation of glucose transporters (GLUT1 and GLUT3), 
epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR), and other growth promoting signals such as pro-
tein kinase C-α (PKC-α), peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ, glial cell line-derived neurotophic fac-
tor (GDNF), and its receptor, rearranged during transfection (RET) receptor. The levels of hypoxia inducible factor-1α (HIF1α), 
prolyl hydroxylase (PHD) enzyme and cytochrome c regulated by hyperglycemia are associated with antiapoptotic activity of 
cancer cells. Cancer cell migration and invasiveness is acquired by the up-regulation of superoxide dismutase (SOD), urokinase 
plasminogen activator (uPA), ZRT/IRT-like protein 6 (ZIP6), and ZRT/IRT-like protein 10 (ZIP10). Moreover, hyperglycemic 
memory, i.e., epigenetic regulation of cancer cells by hyperglylcemia, increases the expression of nuclear factor-κB (NF-κB) and 
neuregulin-1 (Nrg1), both are well-established oncogenic signals. 
333
Hyperglycemia and cancer 
Diabetes Metab J 2014;38:330-336http://e-dmj.org
expression of cancer stem cell markers in basal luminal breast 
carcinoma, which leads to reduced reactive oxygen species 
(ROS) generation and increased cell survival.
 Hydrogen peroxide has been implicated in the migration 
and invasive activity of pancreatic cancer cells under hypergly-
cemic conditions [38]. High glucose levels generate oxidative 
stress due to ROS. The migration and invasion of pancreatic 
cancer cell lines, such as BxPC-3 and Panc-1 cells, are all aug-
mented by superoxide dismutase (SOD) which catalyzes the 
conversion of the superoxide anion to hydrogen peroxide un-
der hyperglycemic conditions [39]. The mRNA expression of 
urokinase plasminogen activator, one of the mediators involved 
in cell migration, is also up-regulated under high glucose levels 
with SOD [40]. 
 Zinc is an essential element for cellular function. An imbal-
ance in zinc homeostasis causes several human diseases [41]. 
Hyperglycemia is thought to promote migration of breast can-
cer cells via zinc and its transporters, ZRT/IRT-like protein 6 
(ZIP6) and ZRT/IRT-like protein 10 (ZIP10) [42]. Thus, high 
glucose increases zinc uptake, and the expression of ZIP6 and 
ZIP10 transporters in breast cancer cells, such as MCF-7. ZIP6 
regulates EMT, and ZIP10 is known to be involved in cancer 
cell migration [43]. 
Epigenetic regulation in cancer cells
Chronic hyperglycemic conditions may cause epigenetic chang-
es in oncogenic pathways in cancer cells (Fig. 1). A recent study 
suggested that epigenetic silencing of the critical gluconeogenic 
enzyme, fructose-1,6-biphosphatase through the EMT-related 
transcription repressor Snail, increases glycolysis and NADPH 
production via the pentose phosphate pathway and a reduction 
in oxidative phosphorylation [37]. These metabolic alterations 
induced by hyperglycemia contribute to lower ROS generation 
and increase of β-catenin/TCF4 activation, a key pathway for 
the acquisition of a cancer stem cell phenotype, leading to better 
survival [37]. Recent studies show that transient hyperglycemia 
induces the recruitment of the transcription factor Set7 to the 
nuclear factor-κB (NF-κB) p65 promoter. The recruitment of 
Set7 to p65 promoter enhances histone 3 lysine 4 monomethyl-
ation within the promoter, resulting in increased NF-κB activa-
tion and increased inflammation [44]. 
 Hyperglycemic memory is an epigenetic phenomenon in-
duced by hyperglycemia [12]. After cancer cells are exposed to 
hyperglycemic conditions, a subset of oncogenic pathways are 
permanently activated, even after hyperglycemic conditions are 
normalized to euglycemic conditions [45]. However, the spe-
cific molecular mechanism how a cancer cell gets permanently 
“rewired” and the hyperglycemic memory instilled is still un-
clear. We suggested that the neuregulin-1 (Nrg1)-HER3 path-
way is up-regulated in tumors derived from hyperglycemic 
patients or rodents. Nrg1 belongs to a family of EGF-like li-
gands for HER3, itself a member of the EGFR of receptor tyro-
sine kinase, related to cancer cell proliferation, survival and 
metastasis [46]. Once activated, these cancer cells originating 
from hyperglycemic conditions grow faster than control cells 
even under euglycemic conditions [45]. 
Therapeutic interventions
Given these strong epidemiological connections seen in patients 
suffering from DM with a higher risk to develop some types of 
cancer, these increased risks need to be taken into account and 
prophylactic screening is warranted. However, an additional 
question is whether antidiabetic therapeutic approaches also re-
duce the risk of associated cancers. 
 There are a variety of antidiabetic interventions, including 
sulfonylureas, α-glucosidase inhibitors, biguanides, and thia-
zolidinediones (TZDs) [47]. The major groups of antidiabetic 
drugs increase the level of circulating insulin, thereby reducing 
hyperglycemia by various mechanisms. Especially, compounds 
such as metformin inhibit hepatic gluconeogenesis to reduce 
the level of circulating glucose and increasing insulin sensitivi-
ty through the 5’AMP-activated protein kinase and AKT/
mTOR pathway [48-50]. Metformin has received widespread 
attention due to its apparent anticancer effects [48,51]. Metfor-
min inhibits cell proliferation and induces apoptosis in cancer 
cell lines [52-54]. It can also exert anticancer effects via modu-
lation of DICER (also known as endoribonuclease Dicer or he-
licase with RNase motif) activity, via mir33a up-regulation, 
and via targeting c-MYC (Myc proto-oncogene protein) [55]. 
Despite a lot of excitement and attention, clinical data inferring 
anti-mitogenic effects of antidiabetic drugs and their effects on 
cancer incidence and mortality remain somewhat controver-
sial. As such, some studies suggest that insulin and insulin 
glargine can increase cancer incidence [56,57], while other 
studies conclude that there is no effect [58]. Similarly, TZDs 
have been reported to exert both tumor growth supporting and 
inhibitory roles [59], whereas metformin and other biguanides 
decrease the cancer incidence [60,61] or have no impact [62]. 
 Another drawback of treating cancers in the context of DM 
is at the level of the memory effects of hyperglycemia and the 
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associated epigenetic alterations in key oncogenic pathways in 
cancer cells. Thus, merely managing blood glucose levels per se 
might not be sufficient to obtain a full therapeutic impact. We 
need to expand our understanding of the key specific target 
genes and pathways affected by hyperglycemia within tumors, 
such that these pathways may be targeted in a more directed 
approach. For instance, the finding that the NRG1/HER3 axis 
is specifically and disproportionately activated in women diag-
nosed with breast cancer and found to be hyperglycemic at the 
time of diagnosis may suggest an effective first line of treatment 
with neutralizing Her3 antibodies which would not necessarily 
be the first choice in the context of other types of breast cancer.
CONCLUSIONS
Strong epidemiological data is at hand suggesting an increase of 
both cancer risk and mortality in DM patients. This is especially 
relevant for cancers of the liver, pancreas, mammary gland, and 
the endometrium. Studies have mainly focused on the molecu-
lar mechanisms related to insulin and chronic inflammation. 
Hyperglycemia and associated hyperglycemic memory effects 
and their impact on key cancer cell pathways, such as cell pro-
liferation, apoptosis, migration, and invasion offer new thera-
peutic avenues. These combined with traditional chemothera-
peutic approaches may offer strong synergistic effects towards 
curbing growth of primary tumors and metastatic lesions. Dia-
betic patients may profit from these more individualized treat-
ment regimens. Unquestionably, with the ever increasing prev-
alence of diabetes in the population, affecting younger individu-
als more than ever before, the interface of metabolic dysregula-
tion and cancer moves increasingly to the forefront and repre-
sents as much of a challenge as it is an opportunity for novel 
therapeutic approaches.
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